Empowered Patient Podcast Karen Jagoda

Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection options to accommodate different lab processes and sample types.  
Ben explains, "When we think about the customer bases we're serving, we're working with many different pharmaceutical companies conducting critical and life-changing research. We just announced a partnership with the Parkinson's Foundation so they can help find ways to gather information and data about patients living with Parkinson's disease. But they need that access and data from patients. By working with Tasso, we enable them to have that reach and accessibility." 
"When we're working with various pharmaceutical companies. They're seeing this real need to get subjects into their trials, to ease recruitment, to help make sure they're hitting their recruitment targets. To help make sure that as a patient goes through a clinical trial, they're able to meet all the data points that are needed so that they can have a completed data set for their own submission. And broadly, in that industry, we're seeing this huge shift. It's really exciting that pharma companies, sponsors, and CROs are looking for more tools to provide patients with better access and lower the barrier, lowering the bar for people to participate in these trials."
#Tassoinc #DecentalizedClinicalTrials #DCT #ClinicalTrials #HealthTechnology #HealthTech
tassoinc.com
Listen to the podcast here

 

Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection options to accommodate different lab processes and sample types.  
Ben explains, "When we think about the customer bases we're serving, we're working with many different pharmaceutical companies conducting critical and life-changing research. We just announced a partnership with the Parkinson's Foundation so they can help find ways to gather information and data about patients living with Parkinson's disease. But they need that access and data from patients. By working with Tasso, we enable them to have that reach and accessibility." 
"When we're working with various pharmaceutical companies. They're seeing this real need to get subjects into their trials, to ease recruitment, to help make sure they're hitting their recruitment targets. To help make sure that as a patient goes through a clinical trial, they're able to meet all the data points that are needed so that they can have a completed data set for their own submission. And broadly, in that industry, we're seeing this huge shift. It's really exciting that pharma companies, sponsors, and CROs are looking for more tools to provide patients with better access and lower the barrier, lowering the bar for people to participate in these trials."
#Tassoinc #DecentalizedClinicalTrials #DCT #ClinicalTrials #HealthTechnology #HealthTech
tassoinc.com
Download the transcript here

Chris Darland, President and CEO of Peerbridge Health, discusses technology breakthroughs that enable early, low-cost detection of heart issues with a cardiac monitor that uses AI to analyze heart rhythms over time to detect patterns that may indicate heart failure. The device is based on ECG technology that drives the Holter monitor and delivers a full 12-lead ECG with a volumetric 3D view of the heart. The goal is to reach more patients who may not proactively seek medical attention and provide early intervention and treatment. 
Chris explains, " I think the problem with the current state is largely that it's too late. And I say that to mean that 80% of all heart failure cases today are getting caught after an emergency room visit. So, it's not necessarily that we don't have the tools to find heart failure and the cardiologists and expertise to identify it, but we're not getting it in time. So if you are one of those patients who, let's say, are caught earlier or maybe unfortunately when you come through the ER, a lot of the tools are existing in the hospital. So you'll get an ultrasound, an echo, to get a view of your heart. We'll do an ECG in the hospital and potentially a cardiac MRI. There's a suite of tools available in the acute care setting that can get to this conclusion relatively quickly if you have all the tools right in front of you."
"The nice part about it is it's relatively accepted from a workflow perspective, a tool that's used quite commonly and has become exceedingly convenient over the last five to 10 years. There is a lot of innovation in a handful of companies to make it easy to wear, light, waterproof, etc. And when we think through the innovation we're working through right now, it's essentially using that tool and the output of this ambulatory cardiac monitor that we have in Peerbridge. Then doing some interesting AI advanced diagnostics on top of it to pick up patterns that were maybe lost historically or potentially missed based on signal fidelity of devices that were in the market. Then using those patterns to try to get a head start on heart failure diagnosis as well as a handful of other things we can show they do."
#PeerbridgeHealth #Cardiology #Cardiologists #ECG #HeartHealth #HeartFailure #EarlyDetection #RemotePatientMonitoring
PeerbridgeHealth.com
Listen to the podcast here
 

Chris Darland, President and CEO of Peerbridge Health, discusses technology breakthroughs that enable early, low-cost detection of heart issues with a cardiac monitor that uses AI to analyze heart rhythms over time to detect patterns that may indicate heart failure. The device is based on ECG technology that drives the Holter monitor and delivers a full 12-lead ECG with a volumetric 3D view of the heart. The goal is to reach more patients who may not proactively seek medical attention and provide early intervention and treatment. 
Chris explains, " I think the problem with the current state is largely that it's too late. And I say that to mean that 80% of all heart failure cases today are getting caught after an emergency room visit. So, it's not necessarily that we don't have the tools to find heart failure and the cardiologists and expertise to identify it, but we're not getting it in time. So if you are one of those patients who, let's say, are caught earlier or maybe unfortunately when you come through the ER, a lot of the tools are existing in the hospital. So you'll get an ultrasound, an echo, to get a view of your heart. We'll do an ECG in the hospital and potentially a cardiac MRI. There's a suite of tools available in the acute care setting that can get to this conclusion relatively quickly if you have all the tools right in front of you."
"The nice part about it is it's relatively accepted from a workflow perspective, a tool that's used quite commonly and has become exceedingly convenient over the last five to 10 years. There is a lot of innovation in a handful of companies to make it easy to wear, light, waterproof, etc. And when we think through the innovation we're working through right now, it's essentially using that tool and the output of this ambulatory cardiac monitor that we have in Peerbridge. Then doing some interesting AI advanced diagnostics on top of it to pick up patterns that were maybe lost historically or potentially missed based on signal fidelity of devices that were in the market. Then using those patterns to try to get a head start on heart failure diagnosis as well as a handful of other things we can show they do."
#PeerbridgeHealth #Cardiology #Cardiologists #ECG #HeartHealth #HeartFailure #EarlyDetection #RemotePatientMonitoring
PeerbridgeHealth.com
Download the transcript here

Dr. David Stein, CEO and Director of Babson Diagnostics, a healthcare technology company that focuses on putting the patient at the center of the blood testing experience, recognizing the importance of blood testing in informing clinical decisions and monitoring health. They aim to redefine blood testing by eliminating the anxiety and inconvenience associated with traditional blood testing methods by offering a more accessible and convenient approach. Blood samples are collected with an innovative device from the patient's fingertip at retail pharmacy locations, and patients use a digital app and QR code system to order and track tests, and receive test results.
David explains, "Babson Diagnostics is a science-first healthcare technology company that has reimagined the end-to-end blood testing experience. In that experience, the patient and customer are the strong focus. We've all experienced times when we've had a blood test ordered for us, and we’ve felt anxious. We've tried, as much as we can, to eliminate that, both by the location where we provide the service, which is the retail pharmacy, and also through our approach, where we easily take samples from your finger, wrap it in a digital layer to make it all understandable. In the end, provide a preferred experience that is much more convenient and accessible than what you experience today."  
"Probably the more important thing is how can we make it so that you don't have to get venipuncture, so that you don't have to get a needle in your arm, because for a significant part of our population, having a sharp object inserted in your body, is not something most of us like. So, in reality, between vasovagal issues and difficult veins, people are looking for a true alternative."
 "People are also looking for accessibility and convenience. What we have innovated is in both aspects. One is to allow you to do broad, clinical-grade testing with a sample that's easily collected from your fingertip while also being able to get that collection done in locations near your home, such as your local supermarket or your local pharmacy. We've tried to innovate in two aspects, which is what everybody wants -- accessibility and convenience. We see that in every part of our economy and have changed the way that blood is collected so that you don’t have the anxiety of a needle going in your arm."
#BabsonDiagnostics #BloodTesting #Pharmacies #BetterWay #MedicalDevice #MedTech
BabsonDX.com
Listen to the podcast here

Dr. David Stein, CEO and Director of Babson Diagnostics, a healthcare technology company that focuses on putting the patient at the center of the blood testing experience, recognizing the importance of blood testing in informing clinical decisions and monitoring health. They aim to redefine blood testing by eliminating the anxiety and inconvenience associated with traditional blood testing methods by offering a more accessible and convenient approach. Blood samples are collected with an innovative device from the patient's fingertip at retail pharmacy locations, and patients use a digital app and QR code system to order and track tests and receive test results.
David explains, "Babson Diagnostics is a science-first healthcare technology company that has reimagined the end-to-end blood testing experience. In that experience, the patient and customer are the strong focus. We've all experienced times when we've had a blood test ordered for us, and we’ve felt anxious. We've tried, as much as we can, to eliminate that, both by the location where we provide the service, which is the retail pharmacy, and also through our approach, where we easily take samples from your finger, wrap it in a digital layer to make it all understandable. In the end, provide a preferred experience that is much more convenient and accessible than what you experience today."  
"Probably the more important thing is how can we make it so that you don't have to get venipuncture, so that you don't have to get a needle in your arm, because for a significant part of our population, having a sharp object inserted in your body, is not something most of us like. So, in reality, between vasovagal issues and difficult veins, people are looking for a true alternative."
 "People are also looking for accessibility and convenience. What we have innovated is in both aspects. One is to allow you to do broad, clinical-grade testing with a sample that's easily collected from your fingertip while also being able to get that collection done in locations near your home, such as your local supermarket or your local pharmacy. We've tried to innovate in two aspects, which is what everybody wants -- accessibility and convenience. We see that in every part of our economy and have changed the way that blood is collected so that you don’t have the anxiety of a needle going in your arm."
#BabsonDiagnostics #BloodTesting #Pharmacies #BetterWay #MedicalDevice #MedTech
BabsonDX.com
Download the transcript here